Apidra launched for adult use in Japan
This article was originally published in Scrip
Executive Summary
Sanofi-Aventis has launched its fast-acting insulin analogue Apidra (insulin glulisine) in Japan, for the management of prandial glycaemic levels in adults with diabetes mellitus.